ERBB2 and gastric cancer: Additionally, a major trial, Trastuzumab for Gastric Cancer (ToGA) trial published in 2010 has shown that combining trastuzumab with conventional chemotherapy notably increased durability in patients with advanced gastric or gastroesophageal (GE) junction carcinomas who were HER2/neu-positive [4].